Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
127.7 USD | -0.14% |
|
-3.91% | +17.15% |
07-01 | Merck, Orion Convert Ongoing Collaboration Into Exclusive Global License for Opevesostat | MT |
07-01 | Merck: license agreement with Orion Corp. for opevesostat | CF |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+17.15% | 323B | |
+55.55% | 816B | |
+41.24% | 634B | |
-6.83% | 351B | |
+7.09% | 293B | |
+13.47% | 238B | |
+1.27% | 222B | |
+13.43% | 218B | |
+7.87% | 167B | |
-3.33% | 158B |
- Stock Market
- Equities
- MRK Stock
- News Merck & Co., Inc.
- Zacks Adjusts Price Target on Merck & Company to $132 From $128